Differential association of adiponectin with cardiovascular risk markers in men and women? The KORA survey 2000

International Journal of Obesity

Volumn 31, Issue 5, 2007, Pages 770-776

  Rathmann, W ^a   Haastert, B ^a   Herder, C ^a   Hauner, H ^b   Koenig, W ^c   Meisinger, C ^d   Holle, R ^d   Giani, G ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY HOSPITAL ULM   (Germany)

^d INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

Adiponectin; Cardiovascular risk; Cholesterol; Epidemiology; Insulin resistance

Indexed keywords

ADIPONECTIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; TRIACYLGLYCEROL; URIC ACID;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DIET RESTRICTION; FACTORIAL ANALYSIS; FEMALE; GERMANY; GLUCOSE TOLERANCE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTIPLE REGRESSION; ORAL GLUCOSE TOLERANCE TEST; POPULATION RESEARCH; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; UNIVARIATE ANALYSIS; WAIST CIRCUMFERENCE;

ADIPONECTIN; AGED; CARDIOVASCULAR DISEASES; FEMALE; GERMANY; HUMANS; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; POPULATION SURVEILLANCE; RISK FACTORS; SEX FACTORS;

EID: 34247494279     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/sj.ijo.0803471     Document Type: Article

References (42)

1. Rabin KR, Kamari Y, Avni I, Grossman E, Sharabi Y. Adiponectin: linking the metabolic syndrome to its cardiovascular consequences. Expert Rev Cardiovasc Ther 2005; 3: 465-471.
2. Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 1996; 271: 10697-10703.
3. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20: 1595-1599.
4. Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003; 23: 85-89.
5. Rothenbacher D, Brenner H, März W, Koenig W. Adiponectin, risk of coronary heart disease and correlations with cardiovascular risk markers. Eur Heart J 2005; 26: 1640-1646.
6. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-843.
7. Reilly MP, Iqbal N, Schutta M, Wolfe ML, Scally M, Localio AR et al. Plasma leptin levels are associated with coronary atherosclerosis in type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 3872-3878.
8. Rothenbacher D, Müller-Scholze S, Herder C, Koenig W, Kolb H. Differential expression of chemokines, risk of stable coronary heart disease, and correlation with established cardiovascular risk markers. Arterioscler Thromb Vasc Biol 2006; 26: 194-199.
9. Dietze-Schroeder D, Sell H, Uhlig M, Koenen M, Eckel J. Autocrine action of adiponectin on human fat cells prevents the release of insulin resistance-inducing factors. Diabetes 2005; 54: 2003-2011.
10. Ouchi N, Kihara S, Funahashi T, Matsuzawa Y, Walsh K. Obesity, adiponectin and vascular inflammatory disease. Curr Opin Lipidol 2003; 14: 561-566.
11. Lindsay R, Resnick H, Ruotolo G. Adiponectin, relationship to proteinuria nut not coronary heart disease: the Strong Heart Study (Abstract). Arterioscler Thromb Vasc Biol 2003; 25: e15-e16.
12. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004; 291: 1730-1737.
13. Schulze MB, Shai I, Rimm EB, Li T, Rifai N, Hu FB. Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes 2005; 54: 534-539.
14. Lawlor DA, Smith GD, Ebrahim S, Thompson C, Sattar N. Plasma adiponectin levels are associated with insulin resistance but do not predict future risk of coronary heart disease in women. J Clin Endocrinol Metab 2005; 90: 5677-5683.
15. Efstathiou SP, Tsioulos DI, Tsiakou AG, Gratsias YE, Pefanis AV, Mountokalakis TD. Plasma adiponectin levels and five-year survival after first-ever ischemic stroke. Stroke 2005; 36: 1915-1920.
16. Söderberg S, Stegmayr B, Stenlund H, Sjöström LG, Agren A, Johansson L et al. Leptin, but not adiponectin, predicts stroke in males. J Int Med 2004; 256: 128-136.
17. Rathmann W, Haastert B, Icks A, Loewel H, Meisinger C, Holle R et al. High prevalence of undiagnosed diabetes mellitus in Southern Germany: target populations for efficient screening. The KORA survey 2000. Diabetologia 2003; 46: 182-189.
18. Chatterjee S, Hadi AS, Price B. Regression analysis by example. Wiley & Sons: New York, 2000.
19. Hanley AJG, Connelly PW, Harris SB, Zinman B. Adiponectin in a Native Canadian population experiencing rapid epidemiological transition. Diabet Care 2003; 26: 3219-3225.
20. Ryo M, Nakamura T, Kihara S, Kumada M, Shibazaki S, Takahashi M et al. Adiponectin as a biomarker of the metabolic syndrome. Circ J 2004; 68: 975-981.
21. Schneider JG, Eynatten M, Schiekofer S, Nawroth PP, Dugi KA. Low plasma adiponectin levels are associated with increased hepatic lipase activity in vivo. Diabet Care 2005; 28: 2181-2186.
22. Böttner A, Kratzsch J, Müller G, Kapellen TM, Blüher S, Keller E et al. Gender differences of adiponectin levels develop during the progression of puberty and are related to serum androgen levels. J Clin Endocrinol Metab 2004; 89: 4053-4061.
23. Nishizawa H, Shimomura I, Kishida K, Maeda N, Kuriyama H, Nagaretani H et al. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 2002; 51: 2734-2741.
24. Lanfranco F, Zitzmann M, Simoni M, Nieschlag E. Serum adiponectin levels in hypogonadal males: influence of testosterone replacement therapy. Clin Endocrinol 2004; 60: 500-507.
25. Cnop M, Havel PJ, Utzschneider KM, Carr DB, Sinha MK, Boyko EJ et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 2003; 46: 459-469.
26. Isobe T, Saitoh S, Takagi S, Takeuchi H, Chiba Y, Katoh N et al. Influence of gender, age and renal function on plasma adiponectin level: the Tanno and Sobetsu study. Eur J Endocrinol 2005; 153: 91-98.
27. Rathmann W, Funkhouser E, Dyer AR, Roseman JM. Relations of hyperuricemia with the various components of the insulin resistance syndrome in young black and white adults: the CARDIA Study. Coronary Artery Risk Development in Young Adults. Ann Epidemiol 1998; 8: 250-261.
28. Kanellis J, Kang DH. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin Nephrol 2005; 25: 39-42.
29. Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, Mu W et al. Hyperuricemia induces endothelial dysfunction. Kidney Int 2005; 67: 1739-1742.
30. Hattori S, Hattori Y, Kasai K. Hypoadiponectinemia is caused by chronic blockade of nitric oxide synthesis in rats. Metabolism 2005; 54: 482-487.
31. Soares AF, Guichardant M, Cozzone D, Bernoud-Hubac N, Buozaidi-Tiali N, Lagarde M et al. Effects of oxidative stress on adiponectin secretion and lactate production in 3T3-L1 adipocytes. Free Radic Biol Med 2005; 38: 882-889.
32. Hayden MR, Tyagi SC. Uric acid: a new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: the urate redox shuttle. Nutr Metab 2004; 1: 1-15.
33. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999; 100: 2473-2476.
34. Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 2000; 102: 1296-1301.
35. Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 2000; 96: 1723-1732.
36. Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001; 103: 1057-1063.
37. Waki H, Yamauchi T, Kamon J, Ito Y, Uchida S, Kita S et al. Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J Biol Chem 2003; 278: 40352-40363.
38. Meigs JB. Invited commentary: insulin resistance syndrome? Syndrome X? Multiple Metabolic Syndrome? A syndrome at all? Factor analysis reveals patterns in the fabric of correlated metabolic risk factors. Am J Epidemiol 2000; 152: 908-911.
39. Pladevall M, Singal B,Williams LK, Brotons C, Guyer H, Sadurni J et al. A single factor underlies the metabolic syndrome. A confirmatory factor analysis. Diabet Care 2006; 29: 113-122.
40. Mohan V, Deepa R, Pradeepa R, Vimaleswaran KS, Mohan A, Velmurugan K et al. Association of low adiponectin levels with the metabolic syndrome - the Chennai Urban Rural Epidemiology Study (CURES-4). Metabolism 2005; 54: 476-481.
41. Xu A, Chan KW, Hoo RLC, Wang Y, Tan KCB, Zhang J et al. Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes. J Biol Chem 2005; 280: 18073-18080.
42. Bobbert T, Rochlitz H, Wegewitz U, Akpulat S, Mai K, Weickert MO et al. Changes of adiponectin oligomer composition by moderate weight reduction. Diabetes 2005; 54: 2712-2719.